



**Supplementary Fig. 1.** Time to early discontinuation stratified by prior anti-TNF usage. Kaplan-Meier analyses for a) all patients and patients who had used b) 0, c) 1 and d)  $\geq 2$  anti-TNFs prior to study commencement. Safety set. TNF: tumour necrosis factor.



**Supplementary Fig. 2.** Mean duration of morning stiffness using MMRM and OC analyses. Full analysis set. MMRM: mixed model with repeated measures; OC: observed case.

Week	0	6	12	24	36	52	64	76	104
n (OC)	838	659	516	484	524	406	350	326	264



**Supplementary Fig. 3.** Percentage of patients reporting a problem in the EQ-5D questionnaire using observed data. Full analysis set. EQ-5D: EuroQol-5 dimension.